Eikon Therapeutics presented updated clinical data at the 2026 ASCO meeting showing encouraging results for its EIK1001 drug in first-line treatment of stage 4 non-small cell lung cancer (NSCLC), with a 63.1% response rate and good tolerability. The company also reported positive safety and efficacy data for EIK1003, a PARP1 inhibitor, both as monotherapy and combined with paclitaxel in advanced solid tumors. These results support continued development of these therapies, which aim to improve cancer treatment outcomes. Eikon plans further trials and data releases in 2026 and beyond.
zSpace, Inc. has converted over $12 million of its outstanding debt into equity through agreements with two lenders, significantly improving its financial position. Fiza Investments converted about $10 million in debt into common and preferred stock ...
Nvidia unveiled new ARM-based hardware at Computex 2026, including the "Vera" CPU designed for AI and data centers. Jim Cramer praised the move, calling it a major positive for ARM Holdings, whose stock has surged over 200% this year. Nvidia is shift...
PMGC Holdings has entered a non-binding letter of intent to acquire a 76% controlling stake in a US-based precision machining company specializing in aerospace, space, defense, and semiconductor markets. The target company, with $5.46 million revenue...
Dividend 15 Split Corp. announced that the Toronto Stock Exchange has approved its Normal Course Issuer Bid (NCIB) to buy back up to 10% of its Preferred and Class A shares. The NCIB starts June 3, 2026, and runs through June 2, 2027, allowing the co...
Kinross Gold Corporation published its 2025 Sustainability Report showcasing its commitment to responsible mining through significant economic contributions of $4.9 billion to host countries and strong performance in environmental, social, and govern...
